
BDX
Becton Dickinson and Company
Company Overview
| Mkt Cap | $53.26B | Price | $154.51 |
| Volume | 2.37M | Change | +0.00% |
| P/E Ratio | 31.7 | Open | $154.56 |
| Revenue | $21.8B | Prev Close | $154.51 |
| Net Income | $1.7B | 52W Range | $153.18 - $213.08 |
| Div Yield | 4.20% | Target | $190.18 |
| Overall | 51 | Value | 95 |
| Quality | 44 | Technical | 16 |
No chart data available
About Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Latest News
3 Best Dividend Aristocrat Stocks to Buy Now, 04/02/2026
BCAL seeks Medicare backing for Avantect pancreatic cancer blood test
Abingdon Health Wins £4.8m U.S. Contracts for Multiplex Lateral Flow Systems
BCAL speeds national rollout of Avantect cancer blood tests
BCAL speeds national rollout of Avantect cancer blood tests
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BDX | $154.51 | 0% | 2.37M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Becton Dickinson and Company Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW